

6-17-2018

# An outbreed mouse model of yellow fever for study of pathogenesis and development of vaccines and therapeutics

Yakhya Dieye

*Institut Pasteur de Dakar, Senegal, Yakhya.Dieye@pasteur.sn*

Moussa Dia

*Institut Pasteur de Dakar, Senegal*

André Bedekelabou

*Institut Pasteur de Dakar*

Ousmane Faye

*Institut Pasteur de Dakar*

Follow this and additional works at: [http://dc.engconfintl.org/vt\\_vii](http://dc.engconfintl.org/vt_vii)



Part of the [Engineering Commons](#)

---

## Recommended Citation

Yakhya Dieye, Moussa Dia, André Bedekelabou, and Ousmane Faye, "An outbreed mouse model of yellow fever for study of pathogenesis and development of vaccines and therapeutics" in "Vaccine Technology VII", Amine Kamen, McGill University Tarit Mukhopadhyay, University College London Nathalie Garcon, Bioaster Charles Lutsch, Sanofi Pasteur Eds, ECI Symposium Series, (2018). [http://dc.engconfintl.org/vt\\_vii/7](http://dc.engconfintl.org/vt_vii/7)

This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Vaccine Technology VII by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).



# An Outbred Mouse Model of Yellow Fever Virus for Study of Pathogenesis and Development of Vaccines and Therapeutics

Yakhya Dièye, Moussa Dia, André P. Bédékélabou and Ousmane Faye

Pôle de Virologie, Institut Pasteur de Dakar, 36 avenue Pasteur, Dakar, Sénégal

## BACKGROUND

Yellow fever (YF) is a mosquito-borne viral disease that is endemic in several countries of sub-Saharan Africa and South America. The World Health Organization estimates that YF causes 200,000 symptomatic cases and 30,000 deaths globally every year, with over 90% of reported cases and deaths occurring in Sub-Saharan Africa. However, other estimates propose much higher figures particularly in Africa. YF prevention is based on a vaccine that exist since 1937. This vaccine is derived from a live attenuated strain of YF virus that confers protection against the seven known YFV genotypes. An important limitation of the currently approved YF vaccines is their manufacture that is a fastidious and lengthy process that requires inoculation of embryonated eggs. This process has a limited capacity for rapid and high scale production to respond to massive outbreaks. Additionally, there are reports of the occurrence of fatal YF vaccine-associated disease which point to the need of new easily manufactured and highly scalable vaccines against YF. Animal models are important to vaccine development. Regarding YF, there are several animal models including mice, hamsters and non-human primates. The small animal models consist mostly of genetically-deficient inbred mice that lack important functions of the immune system. In this work, we are developing a mouse model of YF using the outbred Swiss Webster mouse strain.

## METHODS AND RESULTS

We tested five YFV strains from the collection of the Institut Pasteur de Dakar (Table 1) for their ability to cause disease to Swiss mice after intraperitoneal administration. Virus stocks prepared from human or insect cell lines were well tolerated by the mice. In contrast, viruses collected from brain homogenates of newborn mice caused mortality to adult Swiss rodents after intraperitoneal administration (Table 2).

**Table 1. Characteristics of Yellow Fever Virus strains tested in this study**


STRAINS	YEAR	LOCATION	ORIGIN
YF-IPD1	1973	Ivory Coast	Mosquito
YF-IPD2	1995	Senegal	Mosquito
YF-IPD3	1995	Senegal	Mosquito
YF-IPD4	1995	Senegal	Mosquito
YF-IPD5	1991	Cameroon	Human

**Table 2. Survival of Swiss mice infected with Yellow Fever viruses prepared from insect cell lines or from newborn brain homogenates**

STRAINS	C6-36 (pfu)	BH-High (pfu)	BH-Low (pfu)
YF-IPD1	12/12 ( $5 \times 10^5$ )	0/9 ( $5 \times 10^7$ )	Fig. 1
YF-IPD2	12/12 ( $3 \times 10^5$ )	6/12 ( $10^{10}$ )	8/8 ( $5 \times 10^2$ )
YF-IPD3	12/12 ( $10^5$ )	6/8 ( $10^{10}$ )	5/8 ( $5 \times 10^3$ )
YF-IPD4	12/12 ( $10^5$ )	6/6 ( $10^{10}$ )	6/8 ( $1,5 \times 10^3$ )
YF-IPD5	12/12 ( $10^5$ )	6/6 ( $5 \times 10^5$ )	4/8 ( $10^4$ )


The numbers in the table show the survivors over the total number of mice tested. C6-36, insect cell line; BH-High, high doses of virus from brain homogenates; BH-Low, low doses of virus from brain homogenates.

### Exposure to Yellow Fever Virus does not protect Swiss mice against other flaviviruses




**Figure 3. Exposure to Yellow Fever virus does not protect Swiss mice against West Nile Virus.** Mice survivors of strains YF-IPD 1 and 2 were challenged 1 month after exposure with Lineages 1 (WNV1) or 7 (Koutango, KGT) of West Nile virus.

### Mouse survival to low doses of YF-IPD1



**Figure 1. Strain YF-IPD1 from newborn brain homogenate is virulent at low doses in adult Swiss mice.** Mice were infected by the intraperitoneal route with the indicated doses of virus and survival was followed for 21 days.

### Pre-exposure to viruses from newborn brain homogenates but not from cell lines confers protection against lethal YFV challenge



**Figure 2. Pre-exposure to Yellow Fever viruses from brain homogenates but not from cell lines confer protection against lethal challenge with strain YF-IPD1.** Mice immunized with the 17D Yellow Fever vaccine strain or survivors of the strains tested in this study were challenged one month later with a lethal dose of strain YF-IPD1 and the survival followed for 21 days.

## CONCLUSION

We showed that Yellow Fever virus prepared from brain homogenates of newborn mice can cause lethal disease to outbred Swiss Webster mice. Prior exposure to non-lethal Yellow Fever virus confer protection against this challenge. This model could be used to study the pathogenesis of YF virus and to perform preclinical development of vaccines and therapeutics for YF.